guest ::
| Home > Publications database > Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis. |
| Home > Publications database > Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis. |
| Journal Article | DKFZ-2026-00603 |
; ; ; ; ; ; ; ;
2026
Oxford Univ. Press
Oxford
Abstract: To present a successful case study of anti-CD19 CAR T cell therapy in a patient with relapsing granulomatosis with polyangiitis (GPA).A 69-year-old male patient suffering from relapsing GPA refractory to standardised immunosuppression underwent an experimental therapy involving CD19-targeting chimeric antigen receptor(CAR)T cells. The conditioning regimen consisted of fludarabine and cyclophosphamide. Follow-up intervals scheduled at one to three months' intervals, incorporated evaluations of the Birmingham Vasculitis Activity Score (BVAS), CT scans of the lungs, C-reactive protein (CRP), peripheral white blood cell count (WBC), lactate dehydrogenase, ANCA, immunoglobulin levels, post-CAR T cell treatment surveillance including (CAR)-lymphocyte counts.The patient was diagnosed with GPA involving the lungs in 2019. He showed a relapsed refractory disease course in spite treatment with rituximab, cyclophosphamide, avacopan, azathioprine, leflunomide and prednisolone. At presentation for CAR T cell treatment, the BVAS was 14, inflammation markers were elevated and pulmonary infiltrates were visible on the CT scan. CAR T cell therapy was well-tolerated with no cytokine release syndrome (CRS) or neurotoxicity, and led to rapid improvement of clinical condition, as well as radiological and laboratory test results. CAR T cells expanded with a transient peak but were not anymore detectable in the peripheral blood around day 90. In line, the significant B cell depletion and hypogammaglobulinemia observed post-treatment showed gradual recovery. At the latest follow-up 12-months post-treatment, the patient is in complete remission without further medication.CD19-targeted CAR T cell therapy was safe and efficacious in a patient with relapsed and refractory GPA. CAR T cell therapy has the potential to transform disease management and improve long-term outcomes for affected patients.
Keyword(s): CD19 CAR T cells ; anca ; autoimmune disorders ; vasculitis
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
